Madeleine Johnson

The sample-to-answer system can multiplex up to 12 targets and can run both isothermal assays and RT-PCR with results in 30 minutes or 60 minutes, respectively.

Company executives highlighted recent and upcoming product launches expected to drive growth in its molecular, microbiology, and immunoassay businesses.

Despite recent struggles, the firm remains optimistic about its position as the first and only direct-from-blood sepsis test system.

The firm also said it is carrying excess inventory needed to assemble instruments and components that it acquired to fend off supply chain issues.

The new SpotFire system is significantly faster than other CLIA-waived syndromic tests, and a new test menu could provide even more advantages, the firm said.

For the fourth quarter ended Dec. 31, QuidelOrtho reported revenues of $866.5 million, up 36 percent from $636.9 million in the year-ago quarter and in line with previously reported preliminary revenues.

The firm now anticipates accelerating its commercialization phase by one to two years and will mix and match its technologies going forward.

Qiagen said its non-COVID portfolio grew 8 percent, or 15 percent at constant exchange rates, in Q4, offsetting a decline in COVID-related sales.

The Franklin Lakes, New Jersey-based firm saw a 17 percent decline in its life sciences business due to an expected drop in COVID-19 testing. 

The Boston-based company has developed a loop-mediated amplification assay and a novel lateral flow strip technology.